The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy
Open accessAbstract
Paclitaxel (Taxol®) is a member of the taxane class of anticancer drugs and one of the most common chemotherapeutic agents used against many forms of cancer. Paclitaxel is a microtubule-stabilizer that selectively arrests cells in the G2/M phase of the cell cycle, and found to induce cytotoxicity in a time and concentration-dependent manner. Paclitaxel has been embedded in novel drug formulations, including albumin and polymeric micelle nanoparticles, and applied to many anticancer treatment regimens due to its mechanism of action and radiation sensitizing effects. Though paclitaxel is a major anticancer drug which has been used for many years in clinical treatments, its therapeutic efficacy can be limited by common encumbrances faced by anticancer drugs. These encumbrances include toxicities, de novo refraction, and acquired multidrug resistance (MDR). This article will give a current and comprehensive review of paclitaxel, beginning with its unique history and pharmacology, explore its mechanisms of drug resistance and influence in combination with radiation therapy, while highlighting current treatment regimens, formulations, and new discoveries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., & McPhail, A. T. (1971) · Journal of the American Chemical Society · doi:10.1021/ja00738a045 · Cited by 4,073
ABC Transporters: From Microorganisms to Man
Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Dynamic instability of microtubule growth
Mitchison, T., & Kirschner, M. (1984) · Nature · doi:10.1038/312237a0 · Cited by 3,337 · cited 1×
“Cells are able to tolerate minor fluctuations in the tubulin dynamic, but any significant alteration will prevent mitosis and the process cell division [44].”
BackgroundA surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643 · cited 3×
“The drugs that are primarily transported via ABCB1 are hydrophobic natural products, and include different classes of anticancer drugs such as paclitaxel, doxorubicin, vinblastine and vincristine; as well as more commonly used antiarrhythmic, antihistamine and cholesterol-lowering statin drugs [15].”
BackgroundRowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Taxol: A Novel Investigational Antimicrotubule Agent
Rowinsky, E. K., Cazenave, L. A., & Donehower, R. C. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.15.1247 · Cited by 1,090
ABC transporters in cancer: more than just drug efflux pumps
Fletcher, J. I., Haber, M., Henderson, M. J., & Norris, M. D. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2789 · Cited by 1,018
Kathawala, R. J., Gupta, P., Ashby, C. R., & Chen, Z.-S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.11.002 · Cited by 777
Self-citationMechanisms of Taxol resistance related to microtubules
Orr, G. A., Verdier-Pinard, P., McDaid, H., & Horwitz, S. B. (2003) · Oncogene · doi:10.1038/sj.onc.1206934 · Cited by 727
Hamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602479 · Cited by 565
Rath, O., & Kozielski, F. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3310 · Cited by 496
Taxol: Mechanisms of Action and Resistancea
HORWITZ, S. B., LOTHSTEIN, L., MANFREDI, J. J., MELLADO, W., PARNESS, J., ROY, S. N., SCHIFF, P. B., SORBARA, L., & ZEHEB, R. (1986) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1986.tb38455.x · Cited by 416
Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
Yusuf, R., Duan, Z., Lamendola, D., Penson, R., & Seiden, M. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033333754 · Cited by 354
Novel formulations of taxanes: a review. Old wine in a new bottle?
Hennenfent, K. L., & Govindan, R. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj100 · Cited by 345
Taxol: A novel radiation sensitizer
Tishler, R. B., Schiff, P. B., Geard, C. R., & Hall, E. J. (1992) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(92)90888-o · Cited by 319
Paclitaxel Resistance in Non–Small-Cell Lung Cancer Associated With Beta-Tubulin Gene Mutations
Monzó, M., Rosell, R., Sánchez, J. J., Lee, J. S., O'Brate, A., González-Larriba, J. L., Alberola, V., Lorenzo, J. C., Núñez, L., Ro, J. Y., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1786 · Cited by 306
Multidrug resistance associated proteins in multidrug resistance
Sodani, K., Patel, A., Kathawala, R. J., & Chen, Z.-S. (2012) · Chinese Journal of Cancer · doi:10.5732/cjc.011.10329 · Cited by 300
Self-citationIn Vitro Studies of Taxol as a Radiation Sensitizer in Human Tumor Cells
Liebmann, J., Cook, J. A., Fisher, J., Teague, D., & Mitchell, J. B. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.6.441 · Cited by 267
X-Ray Sensitivity and DNA Synthesis in Synchronous Populations of HeLa Cells
Terasima, T., & Tolmach, L. J. (1963) · Science · doi:10.1126/science.140.3566.490 · Cited by 248
Kamath, K., Wilson, L., Cabral, F., & Jordan, M. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414477200 · Cited by 247
Shi, Y., van der Meel, R., Theek, B., Oude Blenke, E., Pieters, E. H. E., Fens, M. H. A. M., Ehling, J., Schiffelers, R. M., Storm, G., van Nostrum, C. F., et al. (2015) · ACS Nano · doi:10.1021/acsnano.5b00929 · Cited by 214
Analysis of the Drug Resistance Profile of Multidrug Resistance Protein 7 (ABCC10)
Hopper-Borge, E., Chen, Z.-S., Shchaveleva, I., Belinsky, M. G., & Kruh, G. D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3111 · Cited by 198
Self-citationMICROTUBULES AS DRUG RECEPTORS: PHARMACOLOGICAL PROPERTIES OF MICROTUBULE PROTEIN*
Wilson, L. (1975) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1975.tb19201.x · Cited by 195
Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily
Hopper, E., Belinsky, M. G., Zeng, H., Tosolini, A., Testa, J. R., & Kruh, G. D. (2001) · Cancer Letters · doi:10.1016/s0304-3835(00)00646-7 · Cited by 178
Hari, M., Loganzo, F., Annable, T., Tan, X., Musto, S., Morilla, D. B., Nettles, J. H., Snyder, J. P., & Greenberger, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0190 · Cited by 175
Lhommé, C., Joly, F., Walker, J. L., Lissoni, A. A., Nicoletto, M. O., Manikhas, G. M., Baekelandt, M. M. O., Gordon, A. N., Fracasso, P. M., Mietlowski, W. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9807 · Cited by 175
Kelly, R. J., Draper, D., Chen, C. C., Robey, R. W., Figg, W. D., Piekarz, R. L., Chen, X., Gardner, E. R., Balis, F. M., Venkatesan, A. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1725 · Cited by 172
Nature as a remarkable chemist: a personal story of the discovery and development of Taxol
Wani, M. C., & Horwitz, S. B. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000063 · Cited by 169
Bcl-2 Down-Regulation Is a Novel Mechanism of Paclitaxel Resistance
Ferlini, C., Raspaglio, G., Mozzetti, S., Distefano, M., Filippetti, F., Martinelli, E., Ferrandina, G., Gallo, D., Ranelletti, F. O., & Scambia, G. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.1.51 · Cited by 160
Characterization of the Transport Properties of Human Multidrug Resistance Protein 7 (MRP7, ABCC10)
Chen, Z.-S., Hopper-Borge, E., Belinsky, M. G., Shchaveleva, I., Kotova, E., & Kruh, G. D. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.2.351 · Cited by 159
Self-citationMartello, L. A., Verdier‐Pinard, P., Shen, H. J., He, L., Torres, K. E., Orr, G. A., & Horwitz, S. B. (2003) · PubMed · Cited by 158
Taxanes: an overview of the pharmacokinetics and pharmacodynamics
Vaishampayan, U. N., Parchment, R. E., Jasti, B., & Hussain, M. (1999) · Urology · doi:10.1016/s0090-4295(99)00451-3 · Cited by 149
Paclitaxel-Dependent Cell Lines Reveal a Novel Drug Activity
Ganguly, A., Yang, H., & Cabral, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0552 · Cited by 130
Formenti, S. C., Volm, M. D., Skinner, K. A., SPICER, D. V., Cohen, D., Perez, E. A., Bettini, A., Groshen, S. G., Gee, C., Florentine, B. D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.132 · Cited by 127
Vergara, D., Bellomo, C., Zhang, X., Vergaro, V., Tinelli, A., Lorusso, V., Rinaldi, R., LVOV, Y. M., Leporatti, S., & Maffia, M. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.10.014 · Cited by 124
Taxol-dependent mutants of Chinese hamster ovary cells with alterations in alpha- and beta-tubulin.
Schibler, M. J., & Cabral, F. (1986) · The Journal of Cell Biology · doi:10.1083/jcb.102.4.1522 · Cited by 120
Zhao, X.-Q., Xie, J., Chen, X.-G., Sim, H. M., Zhang, X., Liang, Y.-J., Singh, S., Talele, T. T., Sun, Y.-L., Ambudkar, S. V., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.111.076299 · Cited by 97
Self-citationNegishi, T., Koizumi, F., Uchino, H., Kuroda, J.-I., Kawaguchi, T., Naito, S., & Matsumura, Y. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603311 · Cited by 92
Contribution of Abcc10 (Mrp7) to In Vivo Paclitaxel Resistance as Assessed in Abcc10−/− Mice
Hopper-Borge, E. A., Churchill, T., Paulose, C., Nicolas, É., Jacobs, J. D., Ngo, O., Kuang, Y., Grinberg, A., Westphal, H., Chen, Z., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3623 · Cited by 86
Self-citationGanguly, A., Yang, H., & Cabral, F. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1109 · Cited by 84
Multiple Drug Transport Pathways through Human P-Glycoprotein
McCormick, J. W., Vogel, P. D., & Wise, J. G. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00018 · Cited by 79
Oguri, T., Ozasa, H., Uemura, T., Bessho, Y., Miyazaki, M., Maeno, K., 前田, 浩., Sato, S., & Ueda, R. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2088 · Cited by 76
Hepatic metabolism and biliary excretion of Taxol in rats and humans.
Monsarrat, B., Alvinerie, P., Wright, M. R., et al. (1993) · PubMed · Cited by 72
Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318
Chen, L., Liang, Y.-J., Ruan, J., Ding, Y. P., Wang, X., Shi, Z., Gu, L., Yang, X.-P., & Fu, L. (2004) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357043879 · Cited by 64
Kathawala, R. J., Wang, Y., Ashby, C. R., & Chen, Z. (2013) · 癌症:英文版 · doi:10.5732/cjc.013.10122 · Cited by 60
Self-citationConcurrent Paclitaxel and Radiation in the Treatment of Locally Advanced Head and Neck Cancer
Sunwoo, J. B., Herscher, L. L., Kroog, G. S., Thomas, G. R., Ondrey, F. G., Duffey, D. C., Solomon, B. I., Boss, C., Albert, P. S., McCullugh, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.800 · Cited by 59
Vallo, S., Michaelis, M., Rothweiler, F., Bartsch, G. C., Gust, K. M., Limbart, D. M., Rödel, F., Wezel, F., Haferkamp, A., & Cinatl, J. J. (2015) · Translational Oncology · doi:10.1016/j.tranon.2015.04.002 · Cited by 58
Deng, W., Dai, C.-L., CHEN, J.-J., Kathawala, R. J., SUN, Y.-L., CHEN, H.-F., Fu, L., & Chen, Z. (2013) · Oncology Reports · doi:10.3892/or.2013.2362 · Cited by 54
Self-citationNew insights into mechanisms of resistance to microtubule inhibitors
Ganguly, A., & Cabral, F. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.06.001 · Cited by 50
Reversing multidrug resistance by tyrosine kinase inhibitors
He, M., & Wei, M. (2012) · 癌症:英文版 · doi:10.5732/cjc.011.10315 · Cited by 49
Li, Y., Chen, N., Palmisano, M., & Zhou, S. Y. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00026 · Cited by 47
Mitotic Centromere-associated Kinesin (MCAK) Mediates Paclitaxel Resistance
Ganguly, A., Yang, H., Pedroza, M., Bhattacharya, R., & Cabral, F. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.296483 · Cited by 46
Yamaguchi, H., Hishinuma, T., Endo, N., Tsukamoto, H., Kishikawa, Y., Masugi, S. A. T. O., MURAI, Y., Hiratsuka, M., Ito, K., Okamura, C., et al. (2006) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2006.00593.x · Cited by 45
Molecular Basis for Class V β-Tubulin Effects on Microtubule Assembly and Paclitaxel Resistance
Bhattacharya, R., & Cabral, F. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900167200 · Cited by 40
Kathawala, R. J., Sodani, K. S., Chen, K., Patel, A. S., Abuznait, A. H., Anreddy, N., Sun, Y.-L., Kaddoumi, A., Ashby, C. R., & Chen, Z. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0743 · Cited by 40
Self-citationKathawala, R. J., Wei, L., Anreddy, N., Chen, K., Patel, A. S., Alqahtani, S., Zhang, Y.-K., Wang, Y.-J., Sodani, K. S., Kaddoumi, A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2638 · Cited by 35
Self-citationFransson, M. N., Gréen, H., Litton, J., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035394 · Cited by 34
Extracellular stability of nanoparticulate drug carriers
Liu, K. C., & Yeo, Y. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0286-0 · Cited by 26
Ong, V., Liem, N. L. M., Schmid, M., Verrills, N. M., Papa, R. A., Marshall, G. M., MacKenzie, K. L., Kavallaris, M., & Lock, R. B. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.128926 · Cited by 24
Sodani, K. S., Tiwari, A. K., Dai, C., Abuznait, A. H., Patel, A. S., Xiao, Z., Ashby, C. R., Kaddoumi, A., Fu, L., & Chen, Z. (2014) · Journal of cancer research updates · doi:10.6000/1929-2279.2014.03.03.7 · Cited by 1
Self-citation
Cited by
Loh, C.-Y., Chai, J., Tang, T., Wong, W., Sethi, G., Shanmugam, M., Chong, P., & Looi, C. (2019) · Cells · doi:10.3390/cells8101118 · Cited by 1,315
Photosensitizers with Aggregation‐Induced Emission: Materials and Biomedical Applications
Hu, F., Xu, S., & Liu, B. (2018) · Advanced Materials · doi:10.1002/adma.201801350 · Cited by 859
Seca, A., & Pinto, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010263 · Cited by 686
Application of Radiosensitizers in Cancer Radiotherapy
Gong, L., Zhang, Y., Liu, C., Zhang, M., & Han, S. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s290438 · Cited by 479
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
Metadata
- Authors
- Barbuti, A., & Chen, Z.-S.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2015-12-03
- Volume
- 7
- Issue
- 4
- Pages
- 2360-2371
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2181548792
- Cited by
- 269
- References
- 62
- FWCI
- 7.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.